IMPACT OF ANEMIA AND RIBAVIRIN DOSE REDUCTION ON SVR TO A TELAPREVIR-BASED REGIMEN IN PATIENTS WITH HCV GENOTYPE 1 AND PRIOR PEGINTERFERON/RIBAVIRIN TREATMENT FAILURE IN THE PHASE III REALIZE STUDY

被引：0
|
作者：
Roberts, Stuart K. [1 ]
Andreone, Pietro [2 ]
Pol, Stanislas [3 ,4 ]
Younossi, Zobair M. [5 ,6 ]
Diago, Moises [7 ]
Lawitz, Eric [8 ]
Focaccia, Roberto [9 ]
Foster, Graham R. [10 ]
Horban, Andrzej [11 ]
Lonjon-Domanec, Isabelle [12 ]
DeMasi, Ralph [13 ]
van Heeswijk, Rolf [14 ]
Picchio, Gaston [13 ]
Witek, James [13 ]
Zeuzem, Stefan [15 ]
机构：
[1] Alfred Hosp, Dept Gastroenterol, Melbourne, Vic, Australia
[2] Univ Bologna, Bologna, Italy
[3] Univ Paris 05, INSERM, U1016, Paris, France
[4] Cochin Hosp, Assistance Publ Hop Paris, Paris, France
[5] Inova Fairfax Hosp, Ctr Liver Dis, Falls Church, VA USA
[6] Inova Fairfax Hosp, Dept Med, Falls Church, VA USA
[7] Hosp Gen Valencia, Valencia, Spain
[8] Alamo Med Res, San Antonio, TX USA
[9] Emilio Ribas Infect Dis Inst, Sao Paulo, Brazil
[10] Queen Marys Univ London, Inst Cell & Mol Sci, London, England
[11] Med Univ Warsaw, Warsaw, Poland
[12] Janssen Pharmaceut, Paris, France
[13] Tibotec Inc, Titusville, NJ USA
[14] Tibotec BVBA, Beerse, Belgium
[15] Goethe Univ Frankfurt, Med Ctr, Frankfurt, Germany
来源：
HEPATOLOGY | 2011年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1007A / 1008A
页数：2
相关论文
共 50 条
  • [21] MALACHITE-II: Phase 3b Trial of Ombitasvir/Paritaprevir/R and Dasabuvir plus Ribavirin or Telaprevir plus Peginterferon/Ribavirin in Peginterferon/Ribavirin Treatment-Experienced Adults With HCV Genotype 1
    Dore, Gregory J.
    Knysz, Brygida
    Luo, Yan
    Janczewska, Ewa
    Streinu-Cercel, Adrian
    Caruntu, Florin A.
    Motoc, Adriana
    Mazur, Wlodzimierz
    Shaw, David R.
    Tornai, Istvan
    Sasadeusz, Joseph
    Skoien, Richard
    Sullivan, Danielle
    Liu, Xuan
    Podsadecki, Thomas
    GASTROENTEROLOGY, 2015, 148 (04) : S1084 - S1085
  • [22] TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA 2B AND RIBAVIRIN THERAPY FOR GENOTYPE 1 CHRONIC HCV PATIENTS: PHASE 3 STUDY IN JAPAN
    Okanoue, Takeshi
    Hayashi, Norio
    Tsubouchi, Hirohito
    Chayama, Kazuaki
    Toyota, Joji
    Kumada, Hiromitsu
    HEPATOLOGY, 2011, 54 : 985A - 986A
  • [23] Characterization of resistant variants in treatment-experienced genotype-1 HCV patients receiving telaprevir/peginterferon/ribavirin in Phase II clinical trials
    Bartels, D. J.
    Sullivan, J. C.
    Zhang, E. Z.
    Tigges, A. M.
    Dorrian, J. L.
    Kwong, A. D.
    Kieffer, T. L.
    ANTIVIRAL THERAPY, 2010, 15 : A29 - A29
  • [24] HIGH CONCORDANCE BETWEEN SVR12 AND SVR24 IN PATIENTS RECEIVING TELAPREVIR PLUS PEGINTERFERON AND RIBAVIRIN IN THREE PHASE III CLINICAL TRIALS: ADVANCE, ILLUMINATE AND REALIZE
    Luo, D.
    Zeuzem, S.
    Jacobson, I. M.
    Sherman, K.
    Adda, N.
    Wright, C. I.
    Picchio, G.
    Witek, J.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S446 - S447
  • [25] Timing and magnitude of ribavirin dose reduction (RBV DR) do not impact sustained virologic response (SVR) rates with boceprevir (BOC) plus peginterferon alfa-2b/ribavirin (P/RBV) in the Anemia Management Study in chronic HCV genotype 1 patients
    Poordad, Fred
    Lawitz, Eric
    Reddy, K. Rajender
    Afdhal, Nezam
    Hezode, Christophe
    Zeuzem, Stefan
    Lee, Samuel S.
    Calleja, Jose L.
    Brown, Robert S.
    Craxi, Antonio
    Wedemeyer, Heiner
    Bacon, Bruce R.
    Flamm, Steven L.
    Deng, Weiping
    Koury, Kenneth J.
    Pedicone, Lisa
    Dutko, Frank
    Burroughs, Margaret
    Alves, Katia
    Wahl, Janice
    Brass, Clifford
    Albrecht, Janice K.
    Sulkowski, Mark S.
    HEPATOLOGY, 2012, 56 : 269A - 270A
  • [26] Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment
    Reddy, K. Rajender
    Shiffman, Mitchell L.
    Morgan, Timothy R.
    Zeuzem, Stefan
    Hadziyannis, Stephanos
    Hamzeh, Fayez M.
    Wright, Teresa L.
    Fried, Michael
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2007, 5 (01) : 124 - 129
  • [27] Simeprevir versus telaprevir in combination with pegylated interferon and ribavirin in HCV genotype 1-infected patients: the Phase III ATTAIN study
    Hinrichsen, H.
    Reddy, K.
    Zoulim, F.
    Weiland, O.
    Horban, A.
    Taliani, G.
    Stanciu, C.
    Villamil, F.
    George, J.
    Dammers, E.
    Fu, M.
    Kurland, D.
    Lenz, O.
    Ouwerkek-Mahadevan, S.
    Verbinnen, T.
    Schlag, M.
    Jessner, W.
    Zeuzem, S.
    JOURNAL OF VIRAL HEPATITIS, 2014, 21 : 6 - 7
  • [28] Daclatasvir vs telaprevir in combination with peginterferon alfa/ribavirin in treatment-naive patients with HCV genotype 1: phase 3 COMMAND-3 results
    Jacobson, I.
    Zeuzem, S.
    Flisiak, R.
    Knysz, B.
    Lueth, S.
    Zarebska-Michaluk, D.
    Janczewska, E.
    Ferenci, P.
    Diago, M.
    Zignego, A.
    Safadi, R.
    Baruch, Y.
    Abdurakhmanov, D.
    Shafran, S.
    Thabut, D.
    Bruck, R.
    Gadano, A.
    Thompson, A.
    Kopit, J.
    McPhee, F.
    Michener, T.
    Hughes, E.
    Yin, P.
    Noviello, S.
    JOURNAL OF VIRAL HEPATITIS, 2014, 21 : 7 - 8
  • [29] Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin
    Feld, Jordan J.
    Jacobson, Ira M.
    Jensen, Donald M.
    Foster, Graham R.
    Pol, Stanislas
    Tam, Edward
    Jablkowski, Maciej
    Berak, Hanna
    Vierling, John M.
    Yoshida, Eric M.
    Perez-Gomez, Hector R.
    Scalori, Astrid
    Hooper, Gregory J.
    Tavel, Jorge A.
    Navarro, Mercidita T.
    Shahdad, Saba
    Kulkarni, Rohit
    Le Pogam, Sophie
    Najera, Isabel
    Eng, Simon
    Lim, Chin Yin
    Shulman, Nancy S.
    Yetzer, Ellen S.
    JOURNAL OF HEPATOLOGY, 2015, 62 (02) : 294 - 302
  • [30] Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin
    Song, Ze-Zhou
    JOURNAL OF HEPATOLOGY, 2015, 63 (03) : 769 - 770
12345